IIQ 3.09% 50.0¢ inoviq ltd

Ann: Results of BARD1 Ovarian Cancer Study, page-28

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,318 Posts.
    lightbulb Created with Sketch. 11
    How often do you see a stock sitting on something the market hasn't taken much notice of then when it's shoved its face the stock rerates

    old news maybe may be not

    BARD1 Executive Director and CSO, Dr Irmgard Irminger-Finger, said “this study showed that using the POC method, BARD1-Ovarian achieved better sensitivity and specificity in a sample set from multiple-sites with a reduced number of analytes than previously reported in the OC-300 Study.”
 
watchlist Created with Sketch. Add IIQ (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.